AURA stock icon

Aura Biosciences


About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Employees: 89

Funds holding %
of 6,689 funds
Analysts bullish %
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 19

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

7% more funds holding

Funds holding: 72 [Q4 2023] → 77 (+5) [Q1 2024]

1.57% more ownership

Funds ownership: 77.89% [Q4 2023] → 79.46% (+1.57%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

10% less capital invested

Capital invested by funds: $340M [Q4 2023] → $307M (-$32.6M) [Q1 2024]

73% less call options, than puts

Call options by funds: $3.14K | Put options by funds: $11.8K

Research analyst outlook

We haven’t received any recent analyst ratings for AURA.

Financial journalist opinion

Based on 3 articles about AURA published over the past 30 days